11 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 32974447 | Acute thrombosis of everolimus-eluting platinum chromium stent caused by impaired prasugrel metabolism due to cytochrome P450 enzyme 2B6*2 (C64T) polymorphism: a case report. | 2020 Aug | 1 |
2 | 30993551 | Inhibitory Effect of Vonoprazan on the Metabolism of [14C]Prasugrel in Human Liver Microsomes. | 2019 Oct | 1 |
3 | 24245489 | First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor. | 2014 | 1 |
4 | 23615745 | Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness. | 2013 Jul | 2 |
5 | 28520385 | Prasugrel Therapy and CYP Genotype | 2012 | 1 |
6 | 21550074 | Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. | 2011 Nov | 3 |
7 | 21053990 | Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. | 2010 Dec | 1 |
8 | 19047469 | Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. | 2009 Mar | 3 |
9 | 19530977 | Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. | 2009 Aug | 1 |
10 | 18094219 | Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. | 2008 Jan | 4 |
11 | 19122335 | Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. | 2008 | 1 |